The immunological regulation of cancer cachexia and its therapeutic implications

Abstract

Cachexia affects the majority of patients with advanced cancer. It leads to poor surgical and oncological outcomes, and negatively affects quality of life. It has long been reported that components of the host immune system, including pro-inflammatory cytokines such as IL-1α, IL-6, TNF-α and INF-γ, participate in the syndrome of cachexia. Yet therapeutic targeting of these pro-inflammatory factors has not yielded meaningful improvements in cachexia management. More recently, the impact of immune cells in the tumour mass (tumour-associated macrophages) and host circulation (myeloid suppressor cells) has garnered much interest with regards to their role in immune tolerance in cancer. However, their role in the generation of systemic inflammation and cancer cachexia is underexplored and outstanding questions remain. This review summarises the key mediators and targets of immune dysfunction in cancer cachexia. Here we describe the host response including skeletal muscle wasting; highlight the current knowledge gap areas; and report the results of previously trialled immunotherapies. A greater understanding of complex interaction between the tumour, immune system and peripheral tissues in the genesis and maintenance of cancer cachexia is a key step in n identifying future therapeutic targets.

Keywords

Cancer cachexia / interleukins / macrophages / immunotherapy

References

[1] Fearon K,Anker SD,Bruera E.Definition and classification of cancer cachexia: an international consensus..Lancet Oncol2011;12:489-95

[2] Fearon KC,Hustead DS.Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis..Am J Clin Nutr2006;83:1345-50

[3] Porporato PE.Understanding cachexia as a cancer metabolism syndrome..Oncogenesis2016;5:e200 PMCID:PMC5154342

[4] Douglas E.Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score..Cancer Treat Rev2014;40:685-91

[5] Arends J,Baracos V.ESPEN guidelines on nutrition in cancer patients..Clin Nutr2017;36:11-48

[6] Laird B.Treating cancer cachexia: an evolving landscape..Ann Oncol2017;28:2055-6

[7] Shurin MR.Cancer as an immune-mediated disease..ImmunoTargets Ther2012;1:1-6 PMCID:PMC4934149

[8] de Matos-Neto E,dePeriera W,Riccardi D.Systemic inflammation in cachexia - is tumor cytokine expression profile the culprit?.Front Immunol2015;6:1-11 PMCID:PMC4689790

[9] Baracos VE,Korc M,Fearon KCH.Cancer-associated cachexia..Nat Rev Dis Primer2018;4:17105

[10] Tracey K,Cerami A.Cachectin: a hormone that triggers acute shock and chronic cachexia..J Infect Dis1988;157:413-20

[11] Sharma M,Sriram S,McFarlane CD.Molecular targets of cancer cachexia: Opportunities for pharmanutritional approaches..PharmaNutrition2014;2:126-8

[12] Sherry BA,Fong Y,Wei H.Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models..FASEB J1989;3:1956-62

[13] Hayden MS.Regulation of NF-κB by TNF family cytokines..Semin Immunol2014;26:253-66 PMCID:PMC4156877

[14] Cawthorn W.TNF-α and adipocyte biology..FEBS Lett2008;9:117-31 PMCID:PMC4304634

[15] Noguchi Y,Younes R,Brennan M.Tumor-induced alterations in tissue lipoprotein lipase activity and mRNA levels..Cancer Res1991;51:863-9

[16] Torelli G,Moldawer LL,Kim H.Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats..Am J Physiol1999;277:850-5

[17] Llovera M,Lopez-Soriano J,Lopez-Soriano FJ.Protein turnover in skeletal muscle of tumour-bearing mice overexpressing the soluble TNF receptor-1..Cancer Lett1998;130:19-27

[18] Yu Z,Hannink M,Yan Z.Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli..PLoS One2008;3:e2086 PMCID:PMC2361191

[19] Tisdale MJ.Biology of cachexia..J Natl Cancer Inst1997;89:1763-73

[20] Thompson M,Parry B.Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients..Biochim Biophys Acta1993;1180:236-42

[21] Karayiannakis A,Polychronidis A,Bounovas A.Serum levels of tumor necrosis factor-α and nutritional status in pancreatic cancer patients..Anticancer Res2001;21:1355-8

[22] Maltoni M,Nanni O,Pezzi L.Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients..Support Care Cancer1997;5:130-5

[23] Hou YC,Chen HY,Tung HL.Elevated serum interleukin-8 level correlates with cancer-related cachexia and sarcopenia: an indicator for pancreatic cancer outcomes..J Clin Med2018;7:502 PMCID:PMC6306800

[24] Haller O,Weber F.The interferon response circuit: Induction and suppression by pathogenic viruses..Virology2006;344:119-30

[25] Mah A.Metabolic regulation of natural killer cell IFN-γ production..Crit Rev Immunol2016;36:131-47 PMCID:PMC5335907

[26] Stanton S.Clinical significance of tumor-infiltrating lymphocytes in breast cancer..J Immunother Cancer2016;4:59 PMCID:PMC5067916

[27] Palata-Salaman C.Interferons and central regulation of feeding..Am J Physiol1993;263:1222-7

[28] Matthys P,Proost P,Heremans H.Severe cachexia in mice inoculated with interferon-γ-producing tumor cells..Int J Cancer1991;49:77-82

[29] Matthys P,Opdenakker G.Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour associated cachexia..Eur J Cancer1991;27:182-7

[30] Langstein H,Fraker D,Norton JA.The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia..Cancer Res1991;51:2302-6

[31] Gregoire F,Hauser N,Van Damme J.Interferon-gamma and interleukin-1 beta inhibit adipoconversion in cultured rodent preadipocytes..J Cell Physiol1992;151:300-9

[32] Yeh S.Geriatric cachexia: the role of cytokines..Am J Clin Nutr1999;70:183-97

[33] Dinarello C.Interleukin-1 in the pathogenesis and treatment of inflammatory diseases..Blood2011;117:3720-32 PMCID:PMC3083294

[34] Hardardottir I,Feingold K.Cytokines stimulate lipolysis and decrease lipoprotein lipase activity in cultured fat cells by a prostaglandin independent mechanism..Biochem Biophys Res Commun1992;186:237-43

[35] McCarthy H,Williams G.Interleukin-1 beta-induced anorexia and pyrexia in rat: relationship to hypothalamic neuropeptide Y..Am J Physiol1995;269:852-7

[36] Sato T,Meguid M,Rossi Fanelli F.Involvement of plasma leptin, insulin and free tryptophan in cytokine-induced anorexia..Clin Nutr2003;22:139-46

[37] Costelli P,Carbo N,Lopez-Sorianoq F.Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130)..Cancer Lett1995;95:33-8

[38] Strassmann G,Chizzonite R.Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor..J Immunol1993;150:2341-5

[39] Deans DAC,Gilmour H,Ross JA.Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer..Br J Cancer2006;95:1568-75 PMCID:PMC2360731

[40] Wellenstein M,Duits D,Slagter M.Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis..Nature2019;572:538-42 PMCID:PMC6707815

[41] Scheede-Bergdahl C,Trutschnigg B,Haggarty A.Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?.Clin Nutr2012;31:85-8

[42] Zhang D,Zhou Y,Yu B.Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer..BMC Cancer2007;7:45 PMCID:PMC1831781

[43] Miller A,Alhayyani S,Watkins D.Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma..Oncogene2017;36:3059-66

[44] White J.IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm. Translational cancer research..Transl Cancer Res2017;6:280-5 PMCID:PMC6372111

[45] Pettersen K,Degen S,Grosjean J.Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling..Sci Rep2017;7:2046 PMCID:PMC5435723

[46] Rupert J,Narasimhan.IL-6 trans signaling among tumour, muscle and fat mediates pancreatic cancer cachexia..J Cachexia Sarcopenia Muscle2018;9:1121-84

[47] O’Riordain M,Maingay J,Ross J.Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism..Int J Oncol1999;15:823-7

[48] Hishida A,Morimoto Y,Okamoto K.Genetic influence of cytokine polymorphisms on the clinical outcome of Japanese gastrointestinal cancer patients in palliative care..Oncol Lett2019;17:623-9 PMCID:PMC6313183

[49] Johns N,Tan BHL,Sørhaug S.New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss..J Cachexia Sarcopenia Muscle2017;8:122-30 PMCID:PMC5356227

[50] Marvel D.Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected..J Clin Invest2015;125:3356-64 PMCID:PMC4588239

[51] Gajewski T,Fu Y.Innate and adaptive immune cells in the tumor microenvironment..Nat Immunol2013;14:1014-22 PMCID:PMC4118725

[52] Guo C,Sarkar D,Wang X.The role of tumor-associated macrophages in tumor vascularization..Vasc Cell2013;5:20 PMCID:PMC3913793

[53] Cuenca A,Winfield R,Gentile L.Novel role for tumor-induced expansion of myeloid derived cells in cancer cachexia..J Immunol2015;192:6111-9 PMCID:PMC4078793

[54] Erdem M,Jumpertz S,Fragoulis A.Macrophages protect against loss of adipose tissue during cancer cachexia..J Cachexia Sarcopenia Muscle2019;

[55] Tang X,Wang Y,Xiao H.Anti-tumour strategies aiming to target tumour-associated macrophages..Immunology2013;138:93-104 PMCID:PMC3575762

[56] Lindau D,Kroesen M,Adema G.The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells..Immunology2013;138:105-15 PMCID:PMC3575763

[57] Noy R.Tumor-associated macrophages: from mechanisms to therapy..Immunity2015;41:49-61 PMCID:PMC4137410

[58] Laine A,Pandita T.The role of inflammatory pathways in cancer-associated cachexia and radiation resistance..Mol Cancer Res2013;11:967-72 PMCID:PMC4133095

[59] Deshmane S,Amini S.Monocyte chemoattractant protein-1 (MCP-1): an overview..J Interferon Cytokine Res2009;29:313-26 PMCID:PMC2755091

[60] Gooden M,Leffers N,Nijman H.The prognostic influence of tumour inflitrating lymphocytes in cancer: a systematic review with meta analysis..Br J Cancer2011;105:93-103 PMCID:PMC3137407

[61] Albini A,Noonan DM.Contribution to tumour angiogenesis from innate immune cells withing the tumour microenvironment: implications for Immunotherapy..Front Immunol2018;9:527 PMCID:PMC5895776

[62] Singel KL.Neutrophils in the tumour microenvironment: trying to heal the wound that cannot heal..Immunol Rev2016;273:329-43 PMCID:PMC5477672

[63] Sproston NR.Role of C-reactive protein at sites of inflammation and infection..Front Immunol2018;9:754 PMCID:PMC5908901

[64] Laird BJ,McMillan DC,Hjermstad MJ.Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system..Am Assoc Cancer Res2013;19:5456-64

[65] Siebert S,Robertson J.Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases..Pharmacol Rev2015;67:280-309

[66] Maini R,Kalden J,Furst D.Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate..Arthritis Rheum2004;50:1051-65

[67] Marcora S,Mittal G,Maddison P.Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis..Am J Clin Nutr2006;84:1463-72

[68] Wu C,Criswell T,Guttridge D.Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease..Pancreas2013;42:813-8 PMCID:PMC3664263

[69] Jatoi A,Nguyen P,Kugler J.A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group..Cancer2007;110:1396-403

[70] Wiedenmann B,Friess H,Arseneau J.A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia..J Support Oncol2008;6:18-25

[71] Chasen M,Bhargava R.Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia..J Am Med Dir Assoc2011;12:62-7

[72] Tracey K.TNF and other cytokines in the metabolism of septic shock and cachexia..Clin Nutr1992;11:1-11

[73] Hong D,Bruera E,Naing A.MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study..Lancet Oncol2014;15:656-66

[74] Fisher G.A phase III study of xilonix in refractory colorectal cancer patients with weight loss..J Clin Oncol2015;33:685-5

[75] Hickish T,Wyrwicz L,Sarosiek T.MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study..Lancet Oncol2017;18:192-201

[76] Paspaliaris V,DeAndrea R,Tsouvelekas A.Phase I/II study of IP-1510 a novel interleukin-1 receptor antagonist in the management of cancer-related cachexia..J Cachexia Sarcopenia Muscle2011;2:261

[77] Bayliss T,Schuster M,Rigas J.A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer..Expert Opin Biol Ther2011;11:1663-8

[78] Coss C,Phelps M.Cachectic cancer patients: immune to check-point inhibitor therapy?.Clin Cancer Res.2018;24:5787-9 PMCID:PMC6279566

[79] Kollipara R,Batus M,Borgia J.Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival..J Clin Oncol2019;37:e20710

[80] Multani M,Fughhi I,Batus M.Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor therapy in advanced-stage non-small cell lung cancer patients..J Clin Oncol2019;37:e14061

[81] Dolan RD,Horgan PG.The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review..Crit Rev Oncol Hematol2018;132:130-7

[82] Roxburgh CSD.Cancer and systemic inflammation: treat the tumour and treat the host..Br J Cancer2014;110:1409-12 PMCID:PMC3960633

[83] Ter Veer E,Besselink M.Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease..Lancet Oncol2018;19:e151-60